Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2019 | MRD negativity in myeloma patients undergoing maintenance therapy

Benjamin Derman • 15 Sep 2019
IMW 2019
Multiple Myeloma

Benjamin Derman, MD, from the University of Chicago, Chicago, IL, talks about how MRD can be best utilized in the near future. Recorded at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from Benjamin Derman

4:26
The prognostic value of peripheral blood MRD status following Elo-KRd in newly diagnosed myeloma
Benjamin Derman • 1 Dec 2023
3:43
MRD-guided treatment cessation in multiple myeloma
Benjamin Derman • 1 Dec 2023
9:57
Quadruplet therapies for treating MM: the current evidence and the findings of a Phase II trial
Benjamin Derman • 1 Dec 2023
5:25
MRD by mass spectrometry in PB and NGS in BM in patients with multiple myeloma treated with Dara-KRd
Benjamin Derman • 1 Jun 2022

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals